Evidence map›Paper›PMID 37367089›Full record

ArticleHematology reports2023

Risk Factors for Death or Cardiovascular Events after Acute Coronary Syndrome in Patients with Myeloproliferative Neoplasms.

Orly Leiva, Andrew Jenkins, Rachel P Rosovsky, Rebecca K Leaf, Katayoon Goodarzi, Gabriela Hobbs

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Myeloproliferative Neoplasms and Cardiovascular Disease: A Review.Current treatment options in oncology · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Acute Coronary Syndrome in Essential Thrombocythemia and Polycythemia Vera.Heart views : the official journal of the Gulf Heart Association
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Orly LeivaDivision of Cardiovascular Medicine, Department of Medicine, New York University Langone Health, New York, NY 10016, USA.
Andrew JenkinsDepartment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Rachel P RosovskyDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA.
Rebecca K LeafDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA.
Katayoon GoodarziDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA.
Gabriela HobbsDivision of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-0199-9333
Harvard University · USBrigham and Women's Hospital · US

Funding

American Society of Hematology MRHAP
6 · The paper itself

Abstract

Patients with myeloproliferative neoplasms (MPNs) are at increased risk of cardiovascular disease (CVD), including acute coronary syndrome (ACS). However, data on long-term outcomes of patients with MPN who have had ACS and risk factors for all-cause death or CV events post-ACS hospitalization are lacking. We conducted a single-center study of 41 consecutive patients with MPN with ACS hospitalization after MPN diagnosis. After a median follow-up of 80 months after ACS hospitalization, 31 (76%) experienced death or a CV event (myocardial infarction, ischemic stroke, or heart failure hospitalization). After multivariable Cox proportional hazards regression, index ACS within 12 months of MPN diagnosis (HR 3.84, 95% CI 1.44-10.19), WBC ≥ 20 K/µL (HR 9.10, 95% CI 2.71-30.52),

Indexed as

myeloproliferative neoplasmsmyocardial infarctionoutcomesthrombosis

Identifiers

PMID37367089
PMCPMC10298451
OpenAlexW4379793505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.